Compare PAGSEG Inc (PAGS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PAGSEG Inc vs State Street SPDR S&P Biotech ETF — how do they compare? PAGSEG Inc trades at $9.69 (market cap $2.68B), while State Street SPDR S&P Biotech ETF trades at $152.06. The key difference: PAGSEG Inc pays a 10.86% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, PAGSEG Inc nearer its low. Which is the better fit depends on your goals.
| PAGS | XBI | |
|---|---|---|
Market Cap | $2.68B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $12.00 | $164.28 |
52-Week Low | $7.75 | $85.16 |
Enterprise Value | $10.42B | — |
Dividend Yield | 10.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PAGS trades at $9.29, up 2.77% with a bullish technical signal. The stock shows attractive valuation metrics with P/E of 6.57 and P/S of 0.68, trading below book value. Recent earnings showed mixed results with Q4 2025 beating expectations but Q1 2026 missing estimates. The company maintains strong profitability with 10.4% net margin and robust cash flow generation of $7.56B from operations in 2025.
Analyst consensus remains strongly bullish with 62.5% buy ratings, though Brazilian macroeconomic risks and competitive pressures warrant monitoring. The stock presents value opportunity with deep discount valuation while benefiting from Brazil's digital banking growth, though execution on credit expansion and funding costs remain key catalysts.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
